Where Will Gilead Sciences Spend Its Cash?

Gilead Sciences (NASDAQ: GILD) intends to augment its late-stage clinical pipeline and/or product portfolio through a bolt-on acquisition soon, according to comments from newly minted CEO Daniel O'Day during the first-quarter conference call. This decision to focus on business development early on in his tenure is welcome news for the company's long-suffering shareholders.